The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Investigation of the Cause of Death in a Gene-Therapy Trial
Abstract
We present a case of disseminated histoplasmosis, complicated by retroperitoneal bleeding and leading to death, in a patient who was receiving systemic immunosuppressive therapy for rheumatoid arthritis and who was enrolled in a gene-therapy trial. This trial was designed to evaluate intraarticular delivery of a tumor necrosis factor alpha (TNF-alpha) antagonist, through an adeno-associated virus (AAV) type 2 delivery system, for inflammatory arthritis. The patient's receipt of concurrent anti-TNF-alpha therapy and other immunosuppressive therapy while she was living in an area where histoplasmosis was endemic was thought to be the most likely explanation for the infection; the evidence presented suggests that this fatal infection was unlikely to have been related to exposure to the agent administered in the gene-therapy trial. This case reinforces the importance of considering infectious complications, such as those from endemic mycoses, in patients receiving treatment with a TNF-alpha antagonist and the importance of having a well-designed monitoring plan when subjects in a research study become ill. (ClinicalTrials.gov number, NCT00126724.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although clinical gene and cell therapies have had major road blocks in the past, due to unanticipated injuries and death154,155, significant safety improvements have been implemented over the last decade156.”
From CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool (2019) · cites this paper as [155]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Histoplasmosis: a Clinical and Laboratory Update
Kauffman, C. A. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00027-06 · Cited by 1,200
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Integration of Adeno-Associated Virus (AAV) and Recombinant AAV Vectors
McCarty, D. M., Young, S. M., & Samulski, R. J. (2004) · Annual Review of Genetics · doi:10.1146/annurev.genet.37.110801.143717 · Cited by 450
Self-citationImmune Responses to AAV in Clinical Trials
Mingozzi, F., & A. High, K. (2011) · Current Gene Therapy · doi:10.2174/156652311796150354 · Cited by 324
Svenson, M., Geborek, P., Saxne, T., & Bendtzen, K. (2007) · Rheumatology · doi:10.1093/rheumatology/kem261 · Cited by 189
Improvements in diagnosis of histoplasmosis.
Wheat, L. J. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.11.1207 · Cited by 172
Research works printed but not linked: 22
- 10.1016/j.semarthrit.2006.02.001 · DOI · Paper page
- 10.1136/ard.2007.081430 · DOI
- 10.1016/j.semarthrit.2005.01.005 · DOI · Paper page
- 10.1002/jgm.1100 · DOI · Paper page
- 10.1089/hum.2006.174 · DOI
- 10.1038/nrmicro1266 · DOI
- 10.1128/CVI.00071-07 · DOI · Paper page
- 10.1046/j.1365-2141.2000.02466.x · DOI
- 10.1038/sj.mt.6300334 · DOI
- 10.4065/83.2.181 · DOI
- 10.1086/506935 · DOI · Paper page
- 10.1086/429996 · DOI · Paper page
- Weisman MH, 2002, J Rheumatol Suppl, 65, 33
- 10.1086/383317 · DOI · Paper page
- 10.1086/521259 · DOI · Paper page
- 10.1097/01.CCM.0000281468.94108.4B · DOI · Paper page
- 10.1111/j.1538-7836.2007.02313.x · DOI · Paper page
- 10.1007/s00134-002-1430-3 · doi:10.1007/s00134-002-1430-3
- 10.1038/gt.2008.68 · DOI · Paper page
- 10.1016/j.ymthe.2006.05.009 · DOI · Paper page
- 10.2174/156652307782151425 · DOI · Paper page
- 10.1002/(SICI)1096-9071(199911)59:3<406::AID-JMV22>3.0.CO;2-N · DOI · Paper page
Cited by
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Evolution of drug delivery systems: From 1950 to 2020 and beyond
Park, H., Otte, A., & Park, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.030 · Cited by 475
CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool
Brokowski, C., & Adli, M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.044 · Cited by 320
Manufacturing of recombinant adeno-associated viral vectors for clinical trials
Clément, N., & Grieger, J. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.2 · Cited by 286
Evidence for the Failure of Adeno-associated Virus Serotype 5 to Package a Viral Genome ≥8.2 kb
Lai, Y., Yue, Y., & Duan, D. (2010) · Molecular Therapy · doi:10.1038/mt.2009.256 · Cited by 166
Pleticha, J., Heilmann, L. F., Evans, C. H., Asokan, A., Samulski, R. J., & Beutler, A. S. (2014) · Molecular Pain · doi:10.1186/1744-8069-10-54 · Cited by 21
Self-citation
Metadata
- Authors
- Frank, K. M., Hogarth, D. K., Miller, J. L., Mandal, S., Mease, P. J., Samulski, R. J., Weisgerber, G. A., & Hart, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-07-09
- Volume
- 361
- Issue
- 2
- Pages
- 161-169
- ISSN
- 0028-4793
- 1533-4406
- Cited by
- 72
- References
- 7
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.